NCT04669262

BGB-DXP604 Alone and in Combination With BGB-DXP593 in Healthy Participants

A Phase 1, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BGB-DXP604 Alone and in Combination With BGB-DXP593 in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: BeiGene · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The primary objective of this study is to investigate the safety and tolerability of BGB-DXP604 alone and in combination with BGB-DXP593 in healthy participants

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	BGB-DXP604	Administered as intravenous (IV) infusion over 30 to 60 minutes
DRUG	BGB-DXP593	Administered as intravenous (IV) infusion over 30 to 60 minutes
DRUG	Placebo	Placebo to match BGB-DXP593
DRUG	Placebo	Placebo to match BGB-DXP604

Timeline

• Start date: 2020-12-09
• Primary completion: 2021-05-21
• Completion: 2021-05-21
• First posted: 2020-12-16
• Last updated: 2024-10-26
• Results posted: 2024-03-15

Locations

1 site across 1 country: Australia